ARQT Stock Summary and Trading Ideas (Arcutis Biotherapeutics | NASDAQ:ARQT)

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

What symbol and exchange does Arcutis Biotherapeutics shares trade?

Arcutis Biotherapeutics trades on the NASDAQ stock market under the symbol ARQT.

What is Arcutis Biotherapeutics stock price doing today?

As of September 3, 2026, ARQT stock price declined to $23.66 with 1,011,214 million shares trading.

What is Arcutis Biotherapeutics's Beta?

ARQT has a beta of 0.55, meaning it tends to be less sensitive to market movements. ARQT has a correlation of 0.02 to the broad based SPY ETF.

How much is Arcutis Biotherapeutics worth?

ARQT has a market cap of $2.97 billion. This is considered a Mid Cap stock.

How much money does Arcutis Biotherapeutics make?

Last quarter Arcutis Biotherapeutics reported $130 million in Revenue and $.11 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.06.

What is the highest and lowest price Arcutis Biotherapeutics traded in the last 3 year period?

In the last 3 years, ARQT traded as high as $31.77 and as low as $1.76.

What are the top ETFs holding Arcutis Biotherapeutics?

The top ETF exchange traded funds that ARQT belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

Is Arcutis Biotherapeutics (ARQT) a good investment?

ARQT has outperformed the market in the last year with a return of +54.4%, while the SPY ETF gained +21.9%. In the last 3 month period, ARQT beat the market returning +13.8%, while SPY returned +2.0%. However, in the most recent 2 weeks ARQT has underperformed the stock market by returning -10.6%, while SPY returned +0.5%.

What are the support and resistance levels for Arcutis Biotherapeutics (ARQT)?

ARQT support price is $23.15 and resistance is $24.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARQT shares will trade within this expected range on the day.